# Kisspeptin Administration Subcutaneously to Patients With IHH

> **NCT05896293** · PHASE2 · RECRUITING · sponsor: **Stephanie B. Seminara, MD** · enrollment: 36 (estimated)

## Conditions studied

- Hypogonadotropic Hypogonadism

## Interventions

- **DRUG:** kisspeptin 112-121
- **DRUG:** leuprolide acetate

## Key facts

- **NCT ID:** NCT05896293
- **Lead sponsor:** Stephanie B. Seminara, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-03
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896293, "Kisspeptin Administration Subcutaneously to Patients With IHH". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05896293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*